[1]
|
Whitesides GM. The'right'size in nanobiotechnology. Nat Biotechnol, 2003, 21(10): 1161-1165. doi: 10.1038/nbt872 |
[2]
|
Liu Y, Miyoshi H, Nakamura M. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer, 2007, 120(12): 2527-2537. doi: 10.1002/ijc.22709 |
[3]
|
Jain KK. Nanomedicine: application of nanobiotechnology in medical practice. Med Princ Pract, 2008, 17(2): 89-101. doi: 10.1159/000112961 |
[4]
|
Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticleaptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA, 2006, 103(16): 6315-6320. doi: 10.1073/pnas.0601755103 |
[5]
|
Singh S, Ray SS. Polylactide based nanostructured biomaterials and their applications. J Nanosci Nanotechnol, 2007, 7(8): 2596-2615. doi: 10.1166/jnn.2007.909 |
[6]
|
KoganMJ, OlmedoI, HostaL, et al. Peptides and metallicnanoparficles for biomedical applications. Nanomedicine lond, 200 7, 2(3): 287-306. doi: 10.2217/17435889.2.3.287 |
[7]
|
Wollina U, Dummer R, Brockmeyer NH, et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer, 2003, 98(5): 993-1001. doi: 10.1002/cncr.11593 |
[8]
|
Park JW, HongK, KirpotinDB, etal. Anti-HER2immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res, 2002, 8(4): 1172-1181. |
[9]
|
Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticleaptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA, 2006, 103(16): 6315-6320. doi: 10.1073/pnas.0601755103 |
[10]
|
Blagbrough IS, Zara C. Animal models for target diseases in gene therapy—using DNA and siRNA delivery strategies. Pharm Res, 2009, 26(1): 1-18. doi: 10.1007/s11095-008-9646-8 |
[11]
|
Schmieder AH, W inter PM, Caruthers SD, et al. Molecular MR imaging of melanoma an giogenesis with alphanubeta-targeted paramagnetic nanoparticles. Magn Reson Med, 2005, 53(3): 621-627. doi: 10.1002/mrm.20391 |
[12]
|
TkachenkoAG, XieH, LiuY, et al. Cellular trajectories of peptide modified gold particle complexes: comparison of nuclear localization signals and peptide transduction domains. Bioconjugate Chem, 2004, 15(3): 482-490. doi: 10.1021/bc034189q |
[13]
|
Hood JD, Bednarski M, Frausto R, et al. Tumorregression by targeted gene delivery to the neovasculature. Science, 2002, 296(5577): 2404-2407. doi: 10.1126/science.1070200 |
[14]
|
Lee JH, Lee K, Moon SH, et al. All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. Angew Chem Int Ed Engl, 2009, 48(23): 4174-4179. doi: 10.1002/anie.200805998 |
[15]
|
Bodei L, Cremonesi M, Zoboli S, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging, 2003, 30(2): 207-216. doi: 10.1007/s00259-002-1023-y |
[16]
|
Bodei L, Cremonesi M, Grana C, et al. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide(90Y-DOTATOC)in neuroendocrine tumours. Eur J Nucl Med Mol Imaging, 2004, 31(7): 1038-1046. |
[17]
|
Valkema R, Pauwels S, Kvols LK, et al. Survival and response after peptide receptor radionuclide therapy with[90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med, 2006, 36(2): 147-156. doi: 10.1053/j.semnuclmed.2006.01.001 |
[18]
|
熊平, 郭萍, 袁亚莉, 等. 顺磁纳米铁核素的研制及性能分析. 中国生物医学工程学报, 2005, 24(2): 154-156. doi: 10.3969/j.issn.0258-8021.2005.02.006
|
[19]
|
Hamoudeh M, Al Faraj A, Canet-Soulas E, et al. Elaboration of PLLA-based superparamagnetic nanoparticles: characterization, magnetic be-haviour study and in vitro relaxivity evaluation. Int J Pharm, 2007, 338(1-2): 248-257. doi: 10.1016/j.ijpharm.2007.01.023 |